RecruitingEarly Phase 1NCT03228732

The Effects of Fluoxetine and/or DHEA

The Effects of the Selective Serotonin Reuptake Inhibitor, Fluoxetine and/or DHEA, on Neuroendocrine, Autonomic Nervous System and Metabolic Counterregulatory Responses During Repeated Hypoglycemia in T1DM Individuals


Sponsor

University of Maryland, Baltimore

Enrollment

60 participants

Start Date

Dec 19, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). DHEA is a hormone produced naturally in the human body. However, it can be manufactured and is sold as an over-the-counter dietary supplement. The dose the investigators are giving in this study is higher than the usual recommended dosage taken as a supplement for certain medical conditions. (3) To study combined effects of fluoxetine and DHEA during low blood glucose. In the present study, the investigators will measure the participant's body's responses to hypoglycemia when given fluoxetine or DHEA or fluoxetine and DHEA or a placebo (a pill with no fluoxetine or DHEA). Approximately 64 individuals with type 1 diabetes will take part in this study.


Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether two supplements — fluoxetine (an antidepressant) and DHEA (a hormone) — can help people with Type 1 diabetes better manage their blood sugar and overall health. **You may be eligible if...** - You have Type 1 diabetes and are between 18 and 50 years old - Your HbA1c (a measure of long-term blood sugar control) is below 11% - You have no diagnosed diabetic complications such as eye, nerve, or skin damage - Your BMI is under 40 **You may NOT be eligible if...** - You are pregnant or unable to use contraception - You take blood thinners, sedatives, anti-seizure drugs, antidepressants, antipsychotics, opioids, or certain other medications - You have a history of severe depression, mania, or psychosis - You have serious heart, liver, or kidney disease - You have active infections, high fever, or significantly abnormal blood test results - You are HIV, Hepatitis B, or Hepatitis C positive Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo Oral Tablet

There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.

DRUGPlacebo Oral Tablet

There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.

DRUGFluoxetine

There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.

DRUGDHEA

There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.

DRUGFluoxetine and DHEA

There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.


Locations(1)

University of Maryland

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03228732


Related Trials